Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Licenses Gene Engineering Technology from University of Washington

NEW YORK (GenomeWeb News) – Horizon Discovery said this week that it has licensed exclusive worldwide rights from the University of Washington to a gene engineering technology that is used as part of its Genesis platform.
The Cambridge, UK-based firm said that the Genesis platform is used to create patient-relevant disease models, called X-Man cell lines. The firm has developed more than 100 of these cell models that are intended to help drug researchers understand how cancer manifests itself in real patients and to help in the development of personalized therapeutics, diagnostics, and theranostic tests.
The viral-based gene engineering technology is “absolutely essential to generating X-Man lines efficiently and reproducibly,” the firm said in a statement.
“In 2009, we will disseminate our technology (and the products and services based upon it) to all levels of academic, industrial and clinical research and begin the process of co-opting the support of healthcare and political leaders; critical in implementing changes in how personalized treatments are discovered and administered," said Horizon Discovery CEO Chris Torrance.
Terms of the license were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.